Free tool · No account
Clinical trials for lymphoma
Lymphoma trials divide sharply between Hodgkin and the many non-Hodgkin subtypes, and between newly diagnosed and relapsed disease. The specific subtype is the most useful thing to include.
1,660 recruiting trials. Showing a sample.
- recruitingNCT06166706
Current Practice of Ventilation Strategies in Children Undergoing General Anesthesia
Postoperative pulmonary complications (PPCs) are common in children undergoing general anesthesia and are associated with prolonged stay in the hospital and high costs. Development of PPCs is associated with ventilator settings in adult patients undergoing general anesthesia. ...
Listed by the study for Precursor Cell Lymphoblastic Leukemia-Lymphoma. Record updated 2025-04-09.
Sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Full details on ClinicalTrials.gov → - recruitingPhase 2NCT06544785
Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
The goal of this phase II randomized open label study is to compare the rate of complete remission (CR) with undetectable minimal residual disease (uMRD) obtained with zanubrutinib in combination with obinutuzumab with two different schedules of administration of obinutuzumab ...
Listed by the study for Small Lymphocytic Lymphoma. Record updated 2026-06-25.
Sponsored by PETHEMA FoundationFull details on ClinicalTrials.gov → - recruitingPhase 2NCT04002947
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
Background: Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma. Most people with this cancer can be cured. But those who are not cured have a poor prognosis. Researchers want to add another drug to standard treatment see if it can improve the cure r...
Listed by the study for Non-Hodgkin's Lymphoma. Record updated 2026-09-11.
Sponsored by National Cancer Institute (NCI)Full details on ClinicalTrials.gov → - recruitingPhase 3NCT06496308
Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment
This multicenter, open-label, randomized controlled trial aims to evaluate the efficacy and safety of Orelabrutinib in combination with Bendamustine and Rituximab (OBR) versus Bendamustine and Rituximab (BR) in patients with intermediate- to high-risk mantle cell lymphoma (MCL...
Listed by the study for Mantle Cell Lymphoma (MCL). Record updated 2024-07-11.
Sponsored by Ruijin HospitalFull details on ClinicalTrials.gov → - recruitingNCT06795113
Optimization of 18F-FDG PET/CT Response Assessment and Prognostic Evaluation Strategies for High-Metabolism Lymphoma
To develop a novel method for evaluating treatment response in lymphoma by utilizing PET/CT imaging data from patients with high-metabolic lymphoma. This involves comparing end-of-treatment PET (EOT-PET) with interim PET (iPET) results to establish a new response assessment ap...
Listed by the study for Lymphoma. Record updated 2025-01-27.
Sponsored by Ruijin HospitalFull details on ClinicalTrials.gov → - recruitingNANCT05876923
The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients
This clinical trial studies the effect of short-term (acute) and long-term (chronic) exercise on immune characteristics and function (phenotype) of patients with indolent non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Most newly-diagnosed CLL patients have ...
Listed by the study for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Record updated 2026-04-09.
Sponsored by Mayo ClinicFull details on ClinicalTrials.gov → - recruitingNANCT06292741
Autonomic Involvement in Patient With Cognitive Decline
Prospective interventional study with a device for comparing autonomic parameters among patients with different forms of cognitive decline
Listed by the study for Lymphoma, Follicular. Record updated 2026-09-02.
Sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCSFull details on ClinicalTrials.gov → - recruitingEARLY_Phase 1NCT06633341
Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma
A Clinical Study on the Safety and Effectiveness of targeting CD5 CAR-T Cells in the treatment of r/r CD5+ T-lymphoma
Listed by the study for T-lymphoblastic Lymphoma. Record updated 2024-10-09.
Sponsored by Zhejiang UniversityFull details on ClinicalTrials.gov → - recruitingPhase 2NCT06043323
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
To learn about the safety of a drug called axicabtagene ciloleucel given in combination with radiation therapy to patients with relapsed/refractory FL.
Listed by the study for Follicular Lymphoma. Record updated 2026-09-04.
Sponsored by M.D. Anderson Cancer CenterFull details on ClinicalTrials.gov → - recruitingPhase 2NCT05519579
Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia
Changing the schedule of intrathecal chemotherapy to be given before and during blinatumomab will maintain the anti-leukemic effects of this drug while at the same time adding the benefit of limiting the neurotoxicity associated with cytokine release.
Listed by the study for Precursor Cell Lymphoblastic Leukemia-Lymphoma. Record updated 2026-04-20.
Sponsored by Northside Hospital, Inc.Full details on ClinicalTrials.gov →
Data from ClinicalTrials.gov, retrieved 2026-09-16. Study sponsors write and update their own records there, including the recruitment status shown here, and the U.S. government does not review or approve every study listed. A trial showing up here is not a recommendation and not a determination that anyone qualifies. Eligibility is decided by the trial's own doctors.
Refine for your situation
Add whatever you know: an age, a city, a mutation from a pathology report. We'll narrow the list to trials that fit. Describe it in your own words.
Trials for other conditions
What we will never do with your records
This generator runs without an account, and KeptWell itself makes the same promises to every family, regardless of plan or price.
- We won't sell your data.
- Not to advertisers, not to data brokers, not to insurers, not to pharma, not to anyone, in any form, ever.
- We won't train AI models on your records.
- KeptWell does not opt in to model training. OpenAI and Anthropic do not use API inputs or outputs to train their models by default.
- We won't lock you in.
- You can export everything in your circle as a ZIP at any time. Cancellation is one click.
Common questions
- Is this lymphoma trial finder really free?
- Yes. You describe the situation, we search ClinicalTrials.gov and show what matches. No account, no payment, no email required. Nothing you type is saved.
- Does showing up here mean the patient qualifies?
- No. A listing here is not a recommendation, and the U.S. government does not review or approve every study on ClinicalTrials.gov. These are trials worth asking your care team about. Every trial has detailed eligibility criteria that the trial's own doctors evaluate, and many depend on test results and treatment history that only your medical team knows in full.
- How current is this list?
- The trials come directly from ClinicalTrials.gov and are refreshed daily, with the retrieval date shown under the list. Each study record is written and kept up to date by that study's own sponsor, so the recruitment status is what the sponsor last reported. Each result links to the full, live record, and the finder above always runs a fresh search when you use it.
- What should I do with a trial that looks promising?
- Bring it to your oncologist or care team, and mention the NCT number (the ID that starts with NCT). They can tell you whether it is a genuine fit and refer you to the trial site.
Found trials worth discussing? Keep them next to the records.
The next step is a conversation with the care team, and that goes better when the scans, labs, and trial details live in one place everyone in the family can see. That's what KeptWell is: the binder, but it understands what's inside.
Get started
We'll email you a secure sign-in link. It works whether you're new here or already have an account.